ATE173475T1 - Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung - Google Patents

Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung

Info

Publication number
ATE173475T1
ATE173475T1 AT94928054T AT94928054T ATE173475T1 AT E173475 T1 ATE173475 T1 AT E173475T1 AT 94928054 T AT94928054 T AT 94928054T AT 94928054 T AT94928054 T AT 94928054T AT E173475 T1 ATE173475 T1 AT E173475T1
Authority
AT
Austria
Prior art keywords
crystalline
anhydrous
preparations
intravenous use
mofetil mycophenolate
Prior art date
Application number
AT94928054T
Other languages
English (en)
Inventor
Roger Cherng Fu
De-Mei Leung
Jeffrey S Fleitman
Michele C Rizzolio
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Application granted granted Critical
Publication of ATE173475T1 publication Critical patent/ATE173475T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT94928054T 1993-09-15 1994-09-12 Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung ATE173475T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15

Publications (1)

Publication Number Publication Date
ATE173475T1 true ATE173475T1 (de) 1998-12-15

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94928054T ATE173475T1 (de) 1993-09-15 1994-09-12 Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung

Country Status (31)

Country Link
US (2) US5543408A (de)
EP (1) EP0724581B1 (de)
JP (1) JP3411038B2 (de)
KR (1) KR100349772B1 (de)
CN (1) CN1060770C (de)
AT (1) ATE173475T1 (de)
AU (1) AU677435B2 (de)
BR (1) BR9407469A (de)
CA (1) CA2171836C (de)
CZ (1) CZ292423B6 (de)
DE (1) DE69414720T2 (de)
DK (1) DK0724581T3 (de)
ES (1) ES2123831T3 (de)
FI (1) FI119639B (de)
HU (1) HU217300B (de)
IL (1) IL110970A (de)
LT (1) LT4052B (de)
LV (1) LV11326B (de)
MX (1) MXPA94007099A (de)
NO (1) NO314727B1 (de)
NZ (1) NZ273801A (de)
PH (1) PH30685A (de)
PL (1) PL178522B1 (de)
RO (2) RO118075B1 (de)
RU (1) RU2132849C1 (de)
SG (1) SG55006A1 (de)
SI (1) SI9420052B (de)
TW (1) TW370527B (de)
UA (1) UA49797C2 (de)
WO (1) WO1995007902A1 (de)
ZA (1) ZA947088B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (de) * 1998-12-09 2002-11-30 Biocon Ltd
CZ292123B6 (cs) * 2001-06-08 2003-08-13 Ivax Pharmaceuticals S.R.O. Způsob přípravy mykofenolátu mofetilu
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
DE602004015310D1 (de) * 2003-09-11 2008-09-04 Sandoz Ag Verfahren zur herstellung von mycophenolatmofetil
WO2005105768A2 (en) * 2004-04-26 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolic acid and ester derivatives thereof
MXPA06005658A (es) * 2004-04-27 2007-04-10 Teva Gyogyszergyar Zartkoruen Proceso para preparacion de micofenolato mofetil, y otros esteres de acido micofenolico.
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
TWI322147B (en) * 2004-07-20 2010-03-21 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Crystalline mycophenolate sodium
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
EP1917010A2 (de) * 2005-02-08 2008-05-07 Aspreva Pharmaceuticals SA Zusammensetzungen und verfahren zur behandlung von gefäss-, autoimmun- und entzündlichen erkrankungen
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP2436381A1 (de) 2006-06-27 2012-04-04 Sandoz AG Kristallisierung von Halogenwasserstoffen von pharmazeutischen Verbindungen
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
MX386935B (es) 2013-03-14 2025-03-04 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
GB2591396B (en) 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
CA3212370A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
SU1170760A1 (ru) * 1984-02-20 1996-09-20 Ф.Ю. Рачинский Дигидробромид 2-(2-морфолиноэтилтио)бензимидазола, повышающий физическую работоспособность и ускоряющий процессы восстановления после физических нагрузок и длительного стресса
US4753935A (en) 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
FR2653999A1 (fr) * 1989-11-06 1991-05-10 Adir Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
RO118075B1 (ro) 2003-01-30
LT96028A (en) 1996-08-26
HUT75119A (en) 1997-04-28
WO1995007902A1 (en) 1995-03-23
ZA947088B (en) 1996-03-14
PL313480A1 (en) 1996-07-08
CZ78896A3 (en) 1996-10-16
EP0724581B1 (de) 1998-11-18
DK0724581T3 (da) 1999-08-02
NO961075D0 (no) 1996-03-15
UA49797C2 (uk) 2002-10-15
RU2132849C1 (ru) 1999-07-10
RO118427B1 (ro) 2003-05-30
PL178522B1 (pl) 2000-05-31
SI9420052B (sl) 2004-02-29
FI119639B (fi) 2009-01-30
PH30685A (en) 1997-09-16
AU677435B2 (en) 1997-04-24
JPH09502721A (ja) 1997-03-18
LV11326A (lv) 1996-06-20
ES2123831T3 (es) 1999-01-16
FI961169L (fi) 1996-03-13
FI961169A0 (fi) 1996-03-13
CZ292423B6 (cs) 2003-09-17
KR100349772B1 (ko) 2002-12-28
IL110970A (en) 1999-01-26
JP3411038B2 (ja) 2003-05-26
HK1012624A1 (en) 1999-08-06
NO961075L (no) 1996-03-15
CA2171836C (en) 2006-11-14
MXPA94007099A (es) 2004-01-23
TW370527B (en) 1999-09-21
DE69414720T2 (de) 1999-04-08
SG55006A1 (en) 1998-12-21
US5543408A (en) 1996-08-06
LT4052B (en) 1996-10-25
HU9600652D0 (en) 1996-05-28
CN1131420A (zh) 1996-09-18
HU217300B (hu) 1999-12-28
AU7723894A (en) 1995-04-03
IL110970A0 (en) 1994-11-28
DE69414720D1 (de) 1998-12-24
BR9407469A (pt) 1996-11-12
EP0724581A1 (de) 1996-08-07
SI9420052A (en) 1996-12-31
CN1060770C (zh) 2001-01-17
NZ273801A (en) 1997-10-24
NO314727B1 (no) 2003-05-12
US5545637A (en) 1996-08-13
CA2171836A1 (en) 1995-03-23
LV11326B (en) 1996-10-20

Similar Documents

Publication Publication Date Title
DE69414720D1 (de) Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
MY100359A (en) External pharmaceutical composition.
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
GEP20032953B (en) Antitumor Agents
GEP20012516B (en) Tricyclic Compounds Having Activity Specific for Integring, Particularly , avB3 Integrins, Method for Preparation the Same as Drugs and Pharmaceutical Composition Containing Same
DE68929368D1 (de) Cephemderivate und Verfahren zu ihrer Herstellung
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
PT861250E (pt) Derivados de amidina e de isotioureia como inibidores de oxido nitrico sintase
ATE35812T1 (de) Gamma-butyrolactonderivate, verfahren zur herstellung derselben und dieselben als aktive bestandteile enthaltende immunomodulierende zubereitungen.
TW252979B (de)
NO931011L (no) 7-okso-7h-pyrido(1,2,3-de)(1,4)benzoksacin-6-karbonsyrer og -estere
RU94021365A (ru) Производные метилпиперазиназепина, способ их получения, фармацевтическая композиция на их основе и использование производных в качестве фармацевтически активного вещества
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
DE69311295D1 (de) 16-(quaternär-Ammoniak)-substituierte Androstan-Derivate, pharmazeutische Präparate davon und ein Verfahren zu ihrer Herstellung
GEP20033054B (en) 2,4,4-Trisubstituted-1,3-Dioxolane Antifungals
ATE45351T1 (de) 5-thioxo-2-imidazolinyl-benzoesaeuren, deren estern, deren salze und verwandte verbindungen, deren anwendung als herbizide.
DE3850044D1 (de) Azelastin-Embonat, Verfahren zu seiner Herstellung und pharmazeutische Zubereitungen, die als Wirkstoff Azelastin-Embonat enthalten.
DE3484155D1 (de) Fr-900216-verbindung, durch kultivierung von atcc 20577 gewonnen, als aktive therapeutische verbindung genutzt, und sie enthaltende antitumorale pharmazeutische zusammensetzung von fr-900216.
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
ES2076517T3 (es) Ergolinas disustituidas en posiciones 2,13, su preparacion y utilizacion en medicamentos.
RU96124465A (ru) Способ лечения стойких дезадаптационных психовегетативных расстройств
ATE48131T1 (de) N-substituierte 3,4-dihydropyrimidinderivate, verfahren zu deren herstellung und pharmazeutische zusammenstellung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification